This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Viral Infections  • Randomized Controlled Trial  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2004;292:916.

	Since this article does not have an abstract, we have provided the first 141 words of the full text and any section headings.

The National Institute of Allergy and Infectious Diseases is expanding its clinical trial of an experimental West Nile virus (WNV) treatment. The trial opened at 36 sites last September, and it is expected to add about 24 new sites this summer.

The trial is assessing the safety of a product containing WNV antibodies derived from individuals who have high blood levels of these antibodies. These antibodies may have the potential to help patients fight WNV infections.

The trial can enroll up to 110 patients aged 18 years or older who have WNV-related encephalitis or who are at risk of developing this condition. Participants will receive a single intravenous dose of the treatment or one of two placebos.

Additional information is available at http://www.clinicaltrials.gov/show/NCT00068055.

In 2003, more than 9860 cases of WNV were reported, which included 264 deaths.